GLP-1 pills are the next frontier for the weight-loss market.
The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk , Novo, and a smaller biotech prove that an oral option could be as effective as injectables, but Wall Street is waiting to see whether or not patients will prefer a daily pill to a weekly or monthly injectable.
The frontrunner is Lilly's orforglipron, which showed up to 14.7% weight loss in Phase 2 trials at 36 weeks. It has set the bar for other contenders and gives investors confidence in the current injectable market leader's ability to capture market share. Closeup of the big three injectable prescription weight loss medicines: Ozempic, Victoza, and Wegovy.
Dr. Michael Weintraub, an endocrinologist and obesity medicine specialist at NYU Langone Health in New York City, says that competition is necessary because all patients are not the same.
Weight-Loss Market Leaders Clinical Trial Data Eli Lilly Roche
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Eli Lilly is 'the Nvidia of GLP-1' weight-loss drugsPharmaceutical companies have significantly grown over the last year as demand for GLP-1 weight-loss drugs continues to skyrocket. Roundhill Investments CEO ...
Read more »
GLP-1s partly to blame for spike in health insurance costs in 2025GLP-1 use is adding to employer health costs and making it more expensive for employees as well — regardless of whether an employee is on the drug or not.
Read more »
GLP-1 use cases are growing: What it means for pharma stocksSharess of Eli Lilly are moving higher on Tuesday after the company revealed that a recent study, conducted by the company, showed that its weight-loss drug ...
Read more »
Viking Therapeutics could be a new winner in the GLP-1 spaceGLP-1 weight-loss drugs have taken the pharmaceutical world by storm, Novo Nordisk (NVO) and Eli Lilly (LLY) making a name for the class of drugs through...
Read more »
Retail earnings and the consumer, GLP-1 stocks : Market DominationIt's that time of the day again — the final hour of trading — which means it's time for Market Domination with Julie Hyman and Josh Lipton as they cover the ...
Read more »
JPMorgan initiates coverage on GLP-1 entrant Viking TherapeuticsJPMorgan initiates coverage on Viking Therapeutics (VKTX) with an Overweight rating and price target of $80 per share. Viking Therapeutics stock has jumped...
Read more »